No one could be expected to have a good working knowledge of all the receptors in their screening panel.
Secondary Intelligence™ does.
Safety issues contribute to ~25% of the attrition in drug projects. When safety issues occur as a result of secondary pharmacology, there is an option to choose a more selective compound or adjust the chemistry to avoid it.
Currently, to address secondary pharmacology, most biopharmaceutical companies screen their small molecule compounds against a broad panel of off-target receptors.
The key challenge is in interpreting the readout in the context of the predicted plasma concentrations: which of the ‘hits’ are going to contribute adverse effects in clinical development and post-marketing? Get it wrong and there is a price to pay further down the line, when everything is far more expensive.
Our new Secondary Intelligence™ software is the only tool available to address this translational challenge.
- Predict off-target adverse events, earlier, faster and cheaper
- Streamline and standardize your secondary pharmacology analysis
- Increase confidence in risk assessment and go/no go decisions
Researchers can either license our software and use it directly to conduct turnkey secondary pharmacology analysis, or you can rely on our team of scientists to run the analysis for you and provide you with the support that you need to advance your program.
Request a demoEasily evaluate the likelihood of off-target interaction
Secondary Intelligence software identifies the key safety information about each receptor, allowing you to focus on the safety implications of an off-target interaction.
Secondary Intelligence ranks the likelihood of each off-target interaction during clinical use, color-coding in red, amber or green, based on quantitative analysis of clinically used drugs that specifically target that receptor, and on the predicted plasma Cmax of the test compound.
The input data required for a test compound are minimal: the Ki at each off-target receptor, and the predicted plasma Cmax to achieve therapeutic efficacy.
Make more confident decisions on which compounds to move forward
Secondary Intelligence prioritises “receptor interactions of concern” in a variety of data representations and ranks compounds against each other to make quantitatively based decisions as to which compounds to progress.
It is also a powerful tool to investigate the mechanisms of in vivo and clinical findings.
A more efficient and accurate method to predict adverse events
The use of personal opinion and judgement to interpret screening panel readouts is unreliable and difficult to standardise across projects and between individuals. We have rigorously built Secondary Intelligence with robust and consistent methodology, analysis and interpretation.
• Secondary Intelligence assembles curated, organised information for a compound’s secondary pharmacology readouts and analysis in one place
• It provides up-to-date literature-based information on the expected side effects of a given compound if it engages with a particular off-target receptor in clinical use.
• This data enables virtual in vitro to in vivo extrapolation (IVIVE)
Will leads the QSTS team to apply computational approaches to assess the safety of pharmaceuticals and other chemicals. He is an experienced safety pharmacologist, having worked at Syntex, Quintiles and AstraZeneca. He is a former President of the Safety Pharmacology Society.
Chris has over 30 years of experience in drug discovery and development gained at AstraZeneca and Vivonics Preclinical Ltd, and provides expert advice on safety pharmacology and toxicology to the QSTS team.
Will leads the QSTS team to apply computational approaches to assess the safety of pharmaceuticals and other chemicals. He is an experienced safety pharmacologist, having worked at Syntex, Quintiles and AstraZeneca. He is a former President of the Safety Pharmacology Society.
Chris has over 30 years of experience in drug discovery and development gained at AstraZeneca and Vivonics Preclinical Ltd, and provides expert advice on safety pharmacology and toxicology to the QSTS team.